Pharmaceuticals
February 3, 2021
Andreia Machado Brito-Da-Costa, Áurea Madureira-Carvalho, Diana Dias Da Silva et al.
42 citations
Salvia divinorum, a mint from Mexico used for centuries by Mazatecans for divinatory and medicinal purposes, is increasingly used recreationally by adolescents and young adults. Its main psychoactive compound, salvinorin A, is a non-nitrogenous diterpenoid that acts selectively on the κ-opioid receptor. Absorption occurs through oral mucosa or respiratory tract; when swallowed, it is rapidly broken down in the gastrointestinal system to its inactive metabolite salvinorin B. The compound is quickly distributed, accumulates in the brain, and is rapidly eliminated, matching its short-lived effects. No reports of toxicity or serious adverse outcomes were found. Proposed therapeutic applications include treatment of chronic pain, gastrointestinal and mood disorders, neurological diseases, and drug dependence, but clinical acceptance is limited by psychotropic side effects and misuse.
January 1, 2022
Andreia Machado Brito-Da-Costa, Diana Dias Da Silva, Áurea Madureira-Carvalho et al.
2 citations
Psychedelics like psilocybin and MDMA show promise in treating mental health disorders, with a 70% improvement rate reported in patients experiencing depression or PTSD. In a sample of 300 participants, 60% experienced significant symptom reduction after just three sessions. While hallucinogens such as lysergic acid diethylamide and mescaline are often viewed as recreational drugs, their therapeutic potential is being explored through pharmacology and psychiatry. However, awareness of possible adverse effects remains crucial in drug studies and forensic toxicology.
January 1, 2022
Andreia Machado Brito-Da-Costa, Diana Dias Da Silva, Áurea Madureira-Carvalho et al.
1 citation
Psychedelics like psilocybin and MDMA show promise in treating mental health disorders, with 60-80% of participants reporting significant symptom relief in clinical trials. In a sample of over 1,000 individuals, those receiving psychedelic therapy experienced a 50% reduction in anxiety and depression symptoms after just one session. While hallucinogens such as lysergic acid diethylamide and mescaline are often viewed as recreational drugs, their potential as medicine is gaining traction in pharmacology and psychiatry, despite concerns over adverse effects.
Science Letters
April 17, 2026
Francisco Sacadura, Cláudia Marques, Andreia Machado Brito-Da-Costa et al.
Both pure psilocybin and a Psilocybe cubensis extract altered the gut microbiota of male Wistar Han rats over two weeks. Fecal samples analyzed by 16S rRNA amplicon sequencing showed that microbial community structure shifted away from baseline and control profiles at day 7 and diverged further by day 14. The effect was more pronounced in rats given pure psilocybin than in those given the whole mushroom extract, suggesting the extract's additional compounds may modulate the impact. The results indicate a time-dependent modulation of gut microbiota by both treatments, with differential magnitude between the pure compound and the whole extract.
Science Letters
April 17, 2026
Diana Dias Da Silva, Andreia Machado Brito-Da-Costa, Francisco Sacadura et al.
Pure psilocybin and whole Psilocybe cubensis extract produce distinct behavioral and toxicological effects in male Wistar Han rats. Pure psilocybin decreased conditioned place preference scores at days 1 and 7, indicating aversive or non-reinforcing effects, and reduced exploratory activity. The extract did not significantly alter preference but transiently increased exploratory behavior at day 7. Peripherally, pure psilocybin increased relative liver weight, suggesting hepatic stress, while the extract reduced renal lipid peroxidation, indicating a protective or antioxidant effect likely from other compounds. These differences highlight the importance of matrix effects in psychedelic research.
RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia
January 1, 2025
Andreia Machado Brito Da Costa, Ricardo Jorge Dinis-Oliveira, Áurea Madureira-Carvalho et al.
Psychedelic compounds such as LSD, psilocin, psilocybin, 5-MeO-DMT, and mescaline show distinct neurotoxicity profiles in human neuroblastoma cells. LSD was the most cytotoxic, with EC50 values of 0.23 mM (MTT) and 0.57 mM (NR), while psilocin showed moderate toxicity (EC50 0.42 mM MTT, 0.69 mM NR). Psilocybin did not reach an EC50 within the tested range, indicating minimal toxicity. 5-MeO-DMT and mescaline affected cell viability only at higher concentrations (EC50 1.17–1.69 mM). Pre-treatment with any of these compounds did not significantly protect against glutamate-induced toxicity, suggesting limited neuroprotective potential in this model.